🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

SUDEEP PHARMA LIMITED SUDEEPPHRM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.sudeeppharma.com
Company Profile ↓
₹846.35
+9.33% 1Y
Mkt Cap₹9,559.41 Cr
P/E55.28
P/B10.71
Div. Yield0.18%
52W High₹870.20
52W Low₹530.00
Book Value₹78.18
EPS (TTM)₹15.31

Company Overview

Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends to meet the needs across functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations. In addition, the company is involved in manufacturing, developing, buying, selling, importing, exporting, trading, agency, testing, distributing, consigning, stocking, registering, packing, marketing, refining, and processing of pharmaceuticals, nutraceutical and nutrition products, food ingredients, mineral and vitamin blends, or premixes for infant, human and animal nutrition, and other chemical and healthcare products. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 19.7%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 34.6%.

Consistent Profit Growth

Net profit has compounded at 49.2% per year over the last five years.

Healthy Margins

Maintains a net profit margin of 27.1%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.17.

Recent Developments

  • Mar 2026 Revenue of ₹642.00 Cr (+29.1% YoY); net profit ₹174.00 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +29.1%, earnings +25.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.0%, profit CAGR 49.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.03%
1 Year:29.07%

Compounded Profit Growth

5 Years:49.18%
1 Year:25.46%

Stock Price Performance

1 Year:+9.33%
6 Months:+40.73%
3 Months:+31.13%
1 Month:+2.48%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 93% of range
₹530.00 ₹870.20
Trend Signals
  • Price vs 50-DMAAbove
  • RSI (14)58.66 · Neutral
Price Performance
1M+2.48%
3M+31.13%
6M+40.73%
1Y+9.33%
Valuation vs Sector

P/E of 55.28 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 34.6%.
  • Excellent profit margin of 27.1%.
  • Profit CAGR of 49.2% over 5 years.

CONS

  • Trading at a high P/E of 55.3.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
55.28
Industry PE
39.97
Forward P/E
43.74
PEG Ratio
-
Book Value
₹78.18
Price to Book
10.71
P/S
14.91
EV/EBITDA
42.85
Dividend Yield
0.18%

Growth (CAGR)

Revenue 5Y
8.03%
Profit 5Y
49.18%
Revenue (YoY)
29.07%
Earnings (YoY)
25.46%

Profitability & Returns

ROCE
34.57%
ROE
19.71%
ROA
14.81%
Profit Margin
27.10%
Op Margin
32.24%
Gross Margin
50.65%
EPS (Latest Qtr)
₹4.33
EPS (TTM)
₹15.31

Balance Sheet & Liquidity

Debt/Equity
0.17
Quick Ratio
1.69
Current Ratio
2.43
Debt
₹150.00 Cr
Total Assets
₹922.26 Cr
Current Assets
₹480.65 Cr
Working Capital
₹249.36 Cr

Ownership

Promoter Holding
85.61%
Chg in Prom Hold
9.45%
FII / Inst Holding
6.91%
Chg in FII Hold
-1.05%

Financial Snapshot

Enterprise Value
₹9,559.41 Cr
Total Revenue (TTM)
₹642.00 Cr
EBITDA
₹222.00 Cr
Free Cash Flow
₹-49.00 Cr
Operating Cash Flow
₹70.00 Cr
Shares Outstanding
₹11.29 Cr
Gross Margin
50.65%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SUDEEPPHRM SUDEEP PHARMA LIMITED NSEPHARMA 846.35 55.28 ₹9,559.41 Cr 0.18% 34.57% 19.71% 8.03% 49.18%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 149.00 Cr115.54 Cr152.96 Cr124.19 Cr163.00 Cr172.34 Cr182.00 Cr
Cost of Revenue -37.94 Cr67.23 Cr43.81 Cr-60.19 Cr-
Gross Profit -77.60 Cr85.72 Cr80.38 Cr-112.14 Cr-
Operating Expenses 85.00 Cr40.96 Cr28.17 Cr39.44 Cr107.00 Cr56.03 Cr120.00 Cr
Operating Income 60.00 Cr36.63 Cr57.55 Cr40.94 Cr51.00 Cr56.11 Cr59.00 Cr
EBITDA 63.00 Cr41.73 Cr61.35 Cr48.53 Cr55.00 Cr66.81 Cr63.00 Cr
Interest Expense 1.00 Cr1.41 Cr66.52 L1.21 Cr2.00 Cr1.17 Cr2.00 Cr
Pretax Income 62.00 Cr37.66 Cr57.85 Cr44.07 Cr60.00 Cr61.78 Cr63.00 Cr
Tax Provision 13.02 Cr8.94 Cr13.71 Cr12.80 Cr12.60 Cr14.08 Cr14.49 Cr
Net Income 49.00 Cr28.71 Cr44.15 Cr30.81 Cr47.00 Cr47.46 Cr49.00 Cr
Diluted EPS 128.132.54-2.734.714.294.33

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 123.00 Cr215.00 Cr343.00 Cr426.17 Cr454.67 Cr497.41 Cr642.00 Cr
Cost of Revenue ---188.80 Cr172.30 Cr172.26 Cr-
Gross Profit ---237.37 Cr282.36 Cr325.15 Cr-
Operating Expenses 98.00 Cr171.00 Cr276.00 Cr153.44 Cr108.16 Cr144.19 Cr420.00 Cr
Operating Income 22.00 Cr40.00 Cr62.00 Cr83.93 Cr174.21 Cr180.96 Cr207.00 Cr
EBITDA 25.00 Cr44.00 Cr67.00 Cr97.30 Cr186.90 Cr198.09 Cr222.00 Cr
Interest Expense 1.00 Cr1.00 Cr2.00 Cr3.41 Cr3.06 Cr4.66 Cr8.00 Cr
Pretax Income 25.00 Cr43.00 Cr69.00 Cr85.98 Cr174.82 Cr182.84 Cr228.00 Cr
Tax Provision 6.75 Cr9.46 Cr18.63 Cr23.66 Cr41.63 Cr44.15 Cr54.72 Cr
Net Income 18.00 Cr33.00 Cr50.00 Cr62.32 Cr133.19 Cr138.69 Cr174.00 Cr
Diluted EPS 128.02236.60356.045.5211.7912.2815.31

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 131.00 Cr213.00 Cr344.00 Cr420.11 Cr513.87 Cr717.17 Cr1,175.00 Cr
Current Assets ---230.02 Cr275.37 Cr424.12 Cr-
Cash & Equivalents ---10.30 Cr13.98 Cr36.81 Cr-
Inventory ---71.00 Cr66.58 Cr128.67 Cr-
Receivables ---93.71 Cr144.57 Cr185.35 Cr-
Total Liabilities ---196.83 Cr157.83 Cr224.08 Cr-
Current Liabilities ---170.83 Cr137.22 Cr174.76 Cr-
Long Term Debt ---19.94 Cr11.14 Cr39.55 Cr-
Total Debt 20.00 Cr31.00 Cr84.00 Cr83.08 Cr78.08 Cr137.55 Cr150.00 Cr
Total Equity 81.00 Cr114.00 Cr163.00 Cr223.28 Cr356.03 Cr493.09 Cr883.00 Cr
Shares Outstanding ---11.29 Cr11.29 Cr11.29 Cr-

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 10.00 Cr35.00 Cr-3.00 Cr48.40 Cr65.69 Cr48.73 Cr70.00 Cr
Investing Cash Flow -22.00 Cr-40.00 Cr-38.00 Cr-50.02 Cr-49.28 Cr-78.76 Cr-331.00 Cr
Financing Cash Flow 12.00 Cr13.00 Cr51.00 Cr-9.78 Cr-12.73 Cr52.70 Cr247.00 Cr
Capital Expenditure -9.00 Cr-11.00 Cr-74.00 Cr-47.15 Cr-52.46 Cr-64.23 Cr-119.00 Cr
Free Cash Flow 1.00 Cr24.00 Cr-77.00 Cr1.24 Cr13.22 Cr-15.51 Cr-49.00 Cr
Net Change in Cash -08.00 Cr10.00 Cr-11.40 Cr3.67 Cr22.67 Cr-14.00 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---55.7%62.1%65.4%-
Operating Margin % 17.9%18.6%18.1%19.7%38.3%36.4%32.2%
Net Margin % 14.6%15.3%14.6%14.6%29.3%27.9%27.1%
ROE % 22.2%28.9%30.7%27.9%37.4%28.1%19.7%
ROCE % ---33.7%46.3%33.4%-

Shareholding Pattern

Insiders
85.61%
Institutions
6.91%
Public Float
48.05%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SUDEEPPHRM

Google News Fri, 10 Apr 2026

Sudeep Pharma Ltd | Stock Share Price Live - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE00dmxPRUl6YXBqdlE3X25ycS1oUTk2U3F6cEo5WV9MX2JUdXUtaUR4eTRBVEdjb3pjQklwUzNRNTNYUllIMllVcDVNTzhVUWI4TWFOSVpRMk44NXZ2RHA5OS01WmRsMFZuUC0zd3hyN19EdkdL?oc=5" target="_blank">Sudeep Phar…

Google News Fri, 28 Nov 2025

Sudeep Pharma Ltd. Share Price Today - Sudeep Pharma Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPSkgtM0NBYnBCSDFESW9jMkcxdGo2eDFXaTctTHVUUi1BNWYtcEpxcFZZazhBbWdpNDBYQVhWdnJhbms2amNIaURVR1poTW9nVEJ0WjRzLU10clgzOUZUREhJMW5OdVhQbVJ0OE8taUMwMHQtQkE2blNUVFdTUUl3QkxB?oc=5" target=…

Google News Fri, 28 Nov 2025

Sudeep Pharma IPO Listing at ₹730; Sudeep Pharma Share Price Jumps 32% to ₹782.85 - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE1EbUd5QnhvdVNkbTdpd2d1S29zVXZ5SmlXak44LWJqLWwzQjBhQlBOMW1HQXRVZXBZNkNJTHFsRXZpSXBfcFc4VVBKQkgyaF9PYVlIQkZuSHExQVBNV0VoV2xzUmoxa3VTR2c?oc=5" target="_blank">Sudeep Pharma IPO Listin…

Google News Fri, 28 Nov 2025

Sudeep Pharma Q4 Results 2026 - Find Sudeep Pharma Q4 Earnings Result | SUDEEPPHRM Q4 results - livemint.com

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxQaGVCQko3TGV1Y2Q0dGs5WW9Kck9QU2p6WkZWWXlHX09xSkU1YTdEZENCb2Z2X3c2eExpSkVUOWtrb1ZiYTBIdmFSc2o1dmMyUEZ3VlVwSnhwRXVhUlh6ZUJOcHg4blNuMmdtVV9kcVp5ZDB6eHVrWGhYclJaQ20xTkhnTTM?oc=5" targ…

Google News Fri, 28 Nov 2025

Sudeep Pharma Q3 Results 2026 - Find Sudeep Pharma Q3 Earnings Result | SUDEEPPHRM Q3 results - livemint.com

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxQa283c0c5cF9rNTRnRVZ5UVJNdVZqUkEtMWxJUjQ4ZU9GR1Zncm1KRDdKOVhsSFNSTHZ6aGNTRnlFMnBtZnJOVXNtclVYTTZfMGhacTA5SnFTVlNja3RieWp2YU45dnpaWUplQkpvWmRTd090VUZCT0lhb01BSEViTnpZN2w?oc=5" targ…

Google News hu, 20 Nov 2025

Sudeep Pharma Share Price Target 2026, 2027, 2030, 2040, 2050 - shareprice-target.com

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTFBlaXFwczMtZW9oZ19IX1NSNEtBWFVkeW5QUUJMWS1GdGtOYmVCdVV0Q19lTkQzaGUyQ3p2Vmd3ZU11R1VaSS1JTXh6R1FKRTUwOVpuaEtpeEdOLU9YRk9XWU9JOXdmQzMtTDhzdFd3Ulg?oc=5" target="_blank">Sudeep Pharma Sh…

SUDEEPPHRM — Frequently Asked Questions

What is the current share price of SUDEEP PHARMA LIMITED (SUDEEPPHRM)?

As of 2026-07-15 09:52 IST, SUDEEP PHARMA LIMITED (SUDEEPPHRM) trades at ₹846.35 on NSE. Its 52-week range is ₹530.00 to ₹870.20.

What is the market capitalisation of SUDEEPPHRM?

SUDEEP PHARMA LIMITED (SUDEEPPHRM) has a market capitalisation of ₹9,559.41 Cr on NSE.

What is the P/E ratio of SUDEEPPHRM?

SUDEEPPHRM trades at a trailing price-to-earnings (P/E) ratio of 55.28. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 10.71.

Does SUDEEPPHRM pay a dividend?

SUDEEP PHARMA LIMITED (SUDEEPPHRM) currently offers a dividend yield of 0.18%.

What is the return on equity (ROE) of SUDEEPPHRM?

SUDEEPPHRM has a return on equity (ROE) of 19.71%. Its return on capital employed (ROCE) is 34.57%.

Is SUDEEPPHRM a good stock to buy?

This page provides a data-driven analysis of SUDEEP PHARMA LIMITED (SUDEEPPHRM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space